Extended versus peripancreatic lymph node dissection for the treatment of left-sided pancreatic cancer.
10.4174/astr.2017.92.6.411
- Author:
Huisong LEE
1
;
Jin Seok HEO
;
Seong Ho CHOI
;
Dong Wook CHOI
Author Information
1. Department of Surgery, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Pancreas;
Neoplasms;
Lymph node excision;
Survival
- MeSH:
Disease-Free Survival;
Follow-Up Studies;
Humans;
Lymph Node Excision*;
Lymph Nodes*;
Lymphatic Metastasis;
Pancreas;
Pancreatic Neoplasms*;
Retrospective Studies;
Tail
- From:Annals of Surgical Treatment and Research
2017;92(6):411-418
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The pathways of lymphatic metastases differ according to the tumor location in pancreatic cancer patients. However, it is unclear whether extended lymph node dissection (LND) is essential for all left-sided pancreatic cancer. The aim of this study is to evaluate the survival outcomes according to the extent of LND and tumor location in patients with left-sided pancreatic cancer. METHODS: January 2005 to December 2013, we retrospectively identified 107 patients who underwent curative intent surgery for left-sided pancreatic cancer. The left-sided pancreatic cancer was defined as a tumor located in pancreatic body or tail. The extent of LND was divided into 2 groups: extended LND and peripancreatic LND. The extended LND group included celiac and superior mesenteric LNs. RESULTS: We included 107 patients with left-sided pancreatic cancer; 59 patients with pancreatic body cancer and 48 patients with pancreatic tail cancer. The median follow-up period was 17 months (range, 3–110 months). Fifty patients with pancreatic body cancer and 30 patients with pancreatic tail cancer underwent extended LND. In patients with pancreatic body cancer, extended LND was associated with improved disease-free survival (DFS) (P = 0.010) and overall survival (P = 0.014). However, extended LND was not associated with DFS in patients with pancreatic tail cancer. CONCLUSION: Extended LND could improve survival in patients with pancreatic body cancer. However, extended LND had no survival benefit for the treatment of pancreatic tail cancer.
